维纳综合征患者的尼古丁胺里酸补充的益处:双盲随机交叉安慰剂受控试验
Mayumi Shoji1,2,3, Hisaya Kato1,2, Masaya Koshizaka1,4
1Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
Aging cell
|June 3, 2025
概括
尼古丁胺 рибоoside (NR) 补充剂改善了动脉硬性和减少皮肤的大小在沃纳综合征 (WS) 患者. 这种NAD+前体对预防WS患者与年龄相关的疾病有前途.
科学领域:
- 老年学是一门学科.
- 代谢医学是一种代谢医学.
- 临床药理学 临床药理学
背景情况:
- 沃纳综合征 (WS) 是一种罕见的遗传疾病,导致过早衰老和相关疾病.
- 尼古丁胺胺氨基二核酸 (NAD+) 枯竭与WS病变产生有关.
- NAD+前体可能为衰老和WS提供治疗益处.
研究的目的:
- 为了评估尼古丁胺 рибоoside (NR) 的安全性和有效性,在患有维纳综合征的患者中.
- 评估NR对NAD+水平,与年龄相关的病理和WS中的代谢概况的影响.
主要方法:
- 一个双盲,随机,交叉,安慰剂对照试验.
- 26周的NR (1000毫克/天) 或安慰剂,其次是交叉.
- 安全性评估,NAD+水平,皮肤,肉,CAVI,ABI和代谢学.
主要成果:
- NR治疗是安全的,没有严重的不良事件.
- 心血管指数 (CAVI) 的显著改善,表明动脉硬性更好.
- 减少皮肤的面积,并趋向于减少脚薄化.
- 代谢分析显示,血液中的肌氨酸水平下降.
结论:
- 尼古丁胺核糖酸 (NR) 对维纳综合征患者来说是安全的,并且可能有益的.
- 在WS中,NR可能有助于预防动脉样硬化,皮肤和功能障碍.
- 补充NR可能是管理加速衰老疾病的治疗策略.
相关概念视频
01:46Electron Transport Chain: Complex I and II
15.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.1K
01:11Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K